
Serine Avagyan, MD, PhD
The goal of our research is to understand how the hematopoietic stem cells (HSCs), their clonal composition and competition, and their progeny affect initiation of blood disorders. Early-onset clonal hematopoietic disorders, including malignant diseases like pediatric MDS or acute myeloid leukemia, are states of significant disturbance of the balanced clonal output. Origins of these early-onset diseases are poorly understood, but likely involve developmental acquisition of mutations that shape hematopoiesis over years. Our long-term goal is to investigate the forces establishing and maintaining clonal fitness and the biologic changes promoting malignant transformation of clones, with a translational goal of prevention of disease in high-risk individuals. Inspired by constantly emerging clinical data and novel technologies, I want to address clinically relevant questions about pathobiology of initiation of clonal blood states with the goal of finding new therapies for devastating blood disease of childhood and young adulthood.
Faculty member of Division of Pediatric Blood and Marrow Transplantation